glp 1 agonist 종류 Dr. Song's Blog: GLP-1 receptor 작용 기전과 효과 약 이야기] 당뇨약이 비만약으로? 유행처럼

The SURMOUNT-MMO trial (ClinicalTrials.gov ID NCT05556512), estimated to be completed in October 2027, is currently studying the role of tirzepatide in people with a BMI 27 kg/m 2 without diabetes, with a high risk for CVD

While early concerns regarding pancreatic and thyroid cancer have been largely attenuated by recent evidence, issues such as gallbladder and biliary disorders, psychiatric safety, and perioperative aspiration risk require ongoing investigation

Molecular Metabolism 4718731

doi: 10.55730/1300-0144.5938, 46

What Do Preclinical Efficacy Studies Indicate

The GCGR occupancy at a dose of 0.12 mg SAR425899 was 11.1% (n = 1)